Following the acquisition of Parabolic Drugs by our Company in 2021, we entered the business of the manufacture and sale of key starting materials, intermediates and APIs, and acquired manufacturing units in Dera Bassi and Lalru in Punjab. Details of our API units are set out below
State-of-the-art manufacturing facilities with global reach, capable of producing APIs at scale
Across Beta-lactams
and General API
Located across
Punjab and Haryana
Annual production
capacity
Serving customers across
25+ countries
Experienced professionals
across our operations
Focused on research,
development and innovation
R&D-driven innovation
and development
Dedicated annual
production capacity
Expertise in diverse methodologies, with a proven track record of developing High Quality APIs.
Equipped to handle a wide range of reaction types, including hazardous and high-pressure reactions
Grignard Reaction
Wittig Reaction
Aldol Condensation Products
Metal Reductions
Oxidation
Hydrogenation Reaction
Metal Hydride Reduction
Amide Coupling
Esterification Reactions
Sandmeyer Reactions
Intramolecular Cyclization
Fischer Indole Synthesis
Silylation Reactions
Friedel-Craft Reactions
Diazotization Reactions
Pall-Knorr Pyrrole Synthesis
Mannich Reaction
Reactions in Cryogenic Reactors
Lyophilization
Preparative HPLC
Enzymatic Reactions
Cryogenic & Photo-sensitive Reactions
Extensive experience in developing APIs for various areas, dedicated to meeting the unique needs of our customers
Our strong scientific capabilities in synthetic chemistry, analytical chemistry and process engineering have helped us build a varied portfolio of 50+ commercial APIs across niche areas including Cephalosporins, Non-Beta-Lactam, Sterile, Oncology, High-Potent (OEB5) and Lyophilized categories. This expertise spans key therapy areas including Cardiovascular/Statins, Anti-Diabetic, CNS/Neuro, Antibiotics, Respiratory, and Gastro-Intestinal. Our DSIR-certified R&D centre at Barwala supports in-house product development, contract research, scale-up and custom synthesis for global customers, backed by a 64-member R&D team and 5 patents filed to date.
Our capabilities include multistep synthesis & scale-up. We have the expertise to perform versatile chemical reactions, route scouting, process development and optimization, QbD implementation, solid state characterization, polymorph screening, chiral chemistry, enzyme technology, and impurity & reference standard synthesis.
Akums has extensive global regulatory expertise focused on international markets. Our top-class quality and cGMP compliance are designed to ensure our products meet stringent quality standards at all times. We have a dedicated team for regulatory affairs. Our team of regulatory affairs understands the complex issues associated with regulatory agencies and assists in the approval of each complex API by analyzing the latest regulatory trends, quality requirements through active monitoring and proactive assessment of potential risks. Akums API business supplies high quality affordable APIs to leading generic formulators across the world, enabling them to accelerate access to affordable medicines for patients worldwide. We are the preferred API partner to pharma companies across the globe. Our business thrives on the deep technical strengths focused in the development and manufacture of complex APIs such as Beta-lactams, non Beta-lactams and highly potent APIs (HPAIs/oncology drugs). This expertise is supported by our strength in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory & quality standards. Akums has extensive global regulatory expertise focused on international markets. All API facilities operate under a unified Quality Management System and are EU-GMP and WHO-GMP certified, in addition to ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018.
Our Accreditations
9001-2015
14001 - 2015
45001 - 2018
GMP
GMP
Manufacturing facilities with advanced capabilities, complemented by dedicated R&D laboratories for continuous innovation.
Dedicated to Cephalosporins API manufacturing across 8 production blocks on a 19-acre site, with an annual capacity of 600 MT/yr and 330 KL multi-step synthesis capability. The facility runs Zero Liquid Discharge operations, supports 900+ personnel, and holds 3 CEPs (Certificates of Suitability) for Cefpodoxime Proxetil, Cefuroxime Axetil and Cefixime Trihydrate.
Manufactures a broad portfolio of non-beta-lactam APIs across 3 production blocks on a 21-acre site, with an annual capacity of 300 MT/yr and 220 KL multi-step synthesis capability. Zero Liquid Discharge facility supporting 500+ personnel, with 2 CEPs currently under process.
A DSIR-certified, state-of-the-art R&D centre for in-house product development, contract research, scale-up and custom synthesis, with a dedicated GMP oncology facility for high-potent (OEB5) synthesis and a separate impurity synthesis lab. Spans 4,207 sq.mt with a 64-member R&D workforce and 5 patents filed, covering General APIs, Heterocyclics, Steroids, Oncology, Cephalosporins & Macrolide Antibiotics, and Intermediates & KSMs.
Partner with Akums to elevate your pharmaceutical, nutraceutical, and cosmetic supply chain. As India's leading CDMO, we offer end-to-end solutions, including R&D, formulation development, and large-scale manufacturing. Our state-of-the-art facilities comply with stringent global standards, ensuring product safety, efficacy, and quality. With a strong focus on innovation, we deliver tailored solutions to meet your unique business needs. Whether you're launching a new product or enhancing your current supply chain, Akums provides reliable expertise, seamless scalability, and unwavering commitment to excellence. Join hands with Akums to strengthen your brand and achieve sustained growth in competitive markets.